📢 Exciting News! 📢Our lab just published a paper on T cell therapy for metastatic breast cancer. I'm incredibly proud of our team, especially @paulshafer94, and I want to thank everyone who contributed to this research. #CancerResearch #Immunotherapy🔬 isct-cytotherapy.org/article/S1465-…

Nominations are now open for Dan L Duncan Comprehensive Cancer Center at Baylor St. Luke's Medical Center on Doximity for U.S. News & World Report's #Cancer hospital rankings. #CancerTwitter, see why we deserve your vote: bsloutcomes.org/cancer @BCMHouston @StLukesHealthD #DLDCCC #MedTwitter

📰BREAKING: Researchers uncover how to target dormant ‘sleeping’ #BreastCancer cells and prevent relapse. Find out more 👇 icr.ac.uk/news-archive/r…

The OXEL trial, led by Filipa Lynce, MD, FASCO, is out on Nature Communications. Among 45 pts with residual TNBC after NAT, adjuvant nivo/cape were well tolerated, increased peripheral immune score & led to numerically improved 2y iDFS (91%) vs nivo (47%) or cape alone (53%). nature.com/articles/s4146…

This one plot completely changed my perspective on US racial statistics. If you just compare raw numbers between black and white Americans, you're very likely comparing young people to old people. That's why you should almost always ask that the numbers be adjusted for age.

A hacker took over Yara Abdou original account including her followers & for reasons unclear to me that X didn’t do anything about it. In any case Dr Abdou started a new account Yara Abdou & she is the best so plz consider following her account Shematologist, MD Aaron Goodman - “Papa Heme”

Proud of my dear friend Yara Abdou for such milestone and on such important and timely topic on minority health in age of precision cancer care.

Great work Yara Abdou on impact of race/ethnicity in long term outcome with RxPonder.

It is very interesting how #IMG come from all over the world and yet share the same basic dreams and hopes. Inspiring talks by Rafeh Naqash, MD and Arya Roy in their US journeys. #ASCO24

A great poster coming from a fantastic group of educators.

Dr. Nadine Tung discusses data from TBCRC048 with great 75% and 37% OOR in mutated gPALB2 and sBRCA1/2 mutations. Data that certainly will benefit Pts with these mutations. #ASCO24 Translational Breast Cancer Research Consortium OncoAlert

This is a great step in the right direction for identifying who can safely forego adjuvant Chemo in N+ RS0-25 premenopause (<55). As Dr. Lisa Carey, MD, ScM, FASCO mentioned, AMH not used for menopause onset. Hope NRG Oncology BR009 accrue enough to inform. #ASCO24 OncoAlert

So proud of Translational Breast Cancer Research Consortium diversity task force leads and two great mentors Erica Stringer-Reasor and Cesar Santa-Maria on co-chairing two great sessions with tons of data that will weeks to unpack! #ASCO24

Catch up the highlights of TBCRC048 and the practice changing updates for germline PALB2 and somatic BRCA patients on Translational Breast Cancer Research Consortium

Within the confines of McCormick, ASCO magically reminds each of its attendees how amazing our craft and its people are. A testament of how kind oncologists are, and how much we care about each other. Thank you #ASCO24 for the yearly reminder.

A great review on long-term AEs. I have typically struggled to describe delayed adverse events succinctly and to clarify their impact on risk-to-benefit calculations. Thank you, Aakash Desai, MD, MPH Cristiane D Bergerot Maryam Lustberg MD, MPH, FASCO Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙

Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in Nature Communications. nature.com/articles/s4146… 🧵

Sitting in a great post-ASCO discussion organized by OncLive.com and chaired by Jason A. Mouabbi MD. Once the dust settles we all need talks like this to actually ingest the data one curve at a time, such as data on benefit of ET in ER-low by Dr. Nasrazadani.

Great work by Dan Landau and amazing team. Tumor-informed MRD panels work but have many limitations (QNS, false Neg etc) . BC late recurrences with minimal DTCs and old biopsies are very challenging. Is novel tumor-agnostic WGS/ML powered approach the future? Great read!

Congrats to ⁦MD Anderson Cancer Center⁩ #IBC program members ⁦Bora Lim, MD⁩ ⁦Angela Alexander PhD⁩ ⁦⁦Naoto T Ueno, MD, PhD⁩ Dr. Nasrazadani for collaborations on Dr. Zhang’s ⁦BCMHouston⁩ work on tumor immunosuppression/myeloid–B cell interactions! nature.com/articles/s4155…